GT Biopharma, Inc. Quarterly Debt-to-equity in % from Q3 2014 to Q1 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
GT Biopharma, Inc. quarterly Debt-to-equity history and growth rate from Q3 2014 to Q1 2024.
  • GT Biopharma, Inc. Debt-to-equity for the quarter ending March 31, 2024 was 68.8 %, a 49.2% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q1 2024 68.8 +22.7 +49.2% Mar 31, 2024
Q4 2023 61.9 +15.1 +32.4% Dec 31, 2023
Q3 2023 52.8 +5.27 +11.1% Sep 30, 2023
Q2 2023 44.8 Jun 30, 2023
Q1 2023 46.1 Mar 31, 2023
Q4 2022 46.8 Dec 31, 2022
Q3 2022 47.5 Sep 30, 2022
Q1 2020 -154 -173 -938% Mar 31, 2020
Q4 2019 -380 -388 -4917% Dec 31, 2019
Q3 2019 539 +535 +13638% Sep 30, 2019
Q2 2019 136 +134 +6910% Jun 30, 2019
Q1 2019 18.4 Mar 31, 2019
Q4 2018 7.89 Dec 31, 2018
Q3 2018 3.92 Sep 30, 2018
Q2 2018 1.94 Jun 30, 2018
Q1 2017 -101 -0.89 -0.89% Mar 31, 2017
Q4 2016 -101 +0.31 +0.31% Dec 31, 2016
Q3 2016 -101 +1.37 +1.34% Sep 30, 2016
Q2 2016 -100 +2.33 +2.27% Jun 30, 2016
Q1 2016 -100 +2.93 +2.84% Mar 31, 2016
Q4 2015 -101 +2.12 +2.05% Dec 31, 2015
Q3 2015 -102 +1.31 +1.27% Sep 30, 2015
Q2 2015 -103 Jun 30, 2015
Q1 2015 -103 Mar 31, 2015
Q4 2014 -103 Dec 31, 2014
Q3 2014 -103 Sep 30, 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.